Table 1 Combination index (CI) and dose reduction index (DRI) of tivozanib and gefitinib combination in T98G and U87MG cells.

From: Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells

Concentrations (μM) fa T98G CI DRI
Tivozanib Gefitinib Tivozanib Gefitinib
10 1 0.64   0.43 2.38 212.76
10 2 0.65   0.41 2.45 113.87
10 5 0.68   0.37 2.84 54.38
10 10 0.7   0.35 3.18 31.78
10 20 0.72   0.35 3.43 17.68
10 50 0.78   0.31 4.69 10.86
U87MG
10 1 0.43   0.72 1.49 21.99
10 2 0.47   0.67 1.65 12.4
10 5 0.49   0.75 1.76 5.35
10 10 0.57   0.74 2.2 3.44
10 20 0.66   0.76 2.95 2.4
10 50 0.86   0.55 6.73 2.47
  1. DRI represents the order of magnitude of dose reduction that is allowed in combination for a given degree of effect as compared with the dose of each drug alone. “fa” denotes fraction affected.